
The FDA approves oral SERD giredestrant for ESR1-mutated breast cancer after a 62% risk cut, tying supply to testing ahead of a November 30, 2026 adjuvant decision.
Taste may be subjective, but it is crucial to patient compliance, particularly for pediatric treatments.
Taste may be subjective, but it is crucial to patient compliance, particularly for pediatric treatments. This article reviews methods used to improve and assess pharmaceutical palatability.
Download
.
over 11 years ago
Advances in Tabletingover 11 years ago
Analytical Techniques for Oral Solid Dosage Formulationover 11 years ago
Simplify Formulation With PATover 11 years ago
Boosting Solubility in Lipid-Based Formulationsover 11 years ago
Innovations in Solid Dosage Equipment





